Investigation of inherited thrombophilias in patients with pulmonary embolism

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 2, 2013, Pages 140-149

  Turan, Onur ^a   Ündar, Bülent ^a   Günay, Türkan ^a   Akkoçlu, Atila ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

inherited thrombophilia; recurrence of pulmonary embolism; thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; DEEP VEIN THROMBOSIS; FACTOR V LEIDEN GENE; FEMALE; GENE; GENE MUTATION; GENETIC RISK; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METHYLENE TETRAHYDROFOLATE REDUCTASE GENE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; PROTHROMBIN GENE; RECURRENT DISEASE; SCREENING; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

FACTOR V; FEMALE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PROTHROMBIN; PULMONARY EMBOLISM; RISK FACTORS; THROMBOPHILIA;

EID: 84873399278     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328359db0e     Document Type: Article

References (45)

1. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: Risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009; 29:298-310
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151:933-938
3. Hooper WC, De Staercke C. The relationship between FV Leiden and pulmonary embolism. Respir Res 2002; 3:8
4. Foy P, Moll S. Thrombophilia: 2009 Update. Curr Treat Options Cardiovasc Med 2009; 11:114-128
5. Demir M, Vural O ?, Sunar H, Altun A, Yorulmaz F, Ozbay G, et al. The prevalence of hereditary thrombophilia in the Trakya region of Turkey. Yonsei Med J 2000; 41:436-440
6. Herold CJ, Bankier AA, Burghuber OC, et al. Pulmonary embolism: Pulmonary vascular disorders, vasculitides, and hemorrhage. In Comprehensive respiratory medicine. Philadelphia: Mosby. 1999; pp. 1-12
7. Silverstein MD, Heit JA, Mohr DN, Peterson TM, O'Fallen WM, Melton LJ 3rd, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998; 158:585-593
8. Prandoni P, Lensing A, Cogo A, Cuppini S, Vilalta S, Carta M, et al. The long-Termclinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7
9. Kruit WH, de Boer AC, Sing AK, van Roon F. The significance of venography in the management of patients with clinically suspected pulmonary embolism. J Intern Med 1991; 230:333-339
10. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003; 58:470-484
11. Schrijver I, Lay MJ, Zehnder JL. Diagnostic single nucleotide polymorphism analysis of factor V Leiden and prothrombin 20210G > A. A comparison of the Nanogen Eelectronic Microarray with restriction enzyme digestion and the Roche LightCycler. Am J Clin Pathol 2003; 119:490-496
12. Nizankowska-Mogilnicka E, Adamek L, Grzanka P, Domagala TB, Sanak M, Krzanowski M, et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur Respir J 2003; 21:25-30
13. A Practical Guide to Laboratory Haemostasis. http://www. practicalhaemostasis. com. [Accessed 29 April 2012
14. Turkish thoracic society diagnosis and treatment report for pulmonary embolism. Turk Thorac J 2009; 10 (SUPPL11
15. Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506
16. Martinelli I, Mannucci PM, De Stefano V. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood 1998; 92:2353-2358
17. De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica 2006; 91:695-698
18. Santamaria MG, Agnelli G, TalianiMR, Prandoni P, Moia M, Bazzan M, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 2005; 116:301-306
19. Bounameaux H. Factor V Leiden paradox: Risk of deepvein thrombosis but not of pulmonary embolism. Lancet 2000; 356:182-183
20. Ivanov P, Komsa-Penkova R, Kovacheva K, Ivanov Y, Stoyanova A, Ivanov I, et al. Impact of thrombophilic genetic factors on pulmonary embolism: Early onset and recurrent incidences. Lung 2008; 186:27-36
21. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344:1222-1231
22. van Sluis GL, Söhne M, El Kheir DY, Trank MW,Gerdes VE, Büller HR, et al. Family history and inherited thrombophilia. J Thromb Haemost 2006; 4:2182-2187
23. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722
24. Ramacciotti E, Wolosker N, Puech-Leao P, Zeratti EA, Gusson PR, del Giglio A, et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 2003; 109:171-174
25. Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Prevalence of factor V Leiden and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis 2007; 23: 31-34
26. Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ, et al. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 1996; 101:406-412
27. Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol Haemost Thromb 2008; 36:131-136
28. Haim N, Lanir N, Hoffman R, et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110:91-96
29. Savaş E, Baltaci V, Şen E, Aras S, Gürkan OU, Alpas I, et al. The frequency of factor V Leiden mutation in patients with lung cancer. Turk Respir J 2003; 4:113-115
30. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet 2003; 362:523-526
31. Bauer KA. The thrombophilias: Well defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135:367-373
32. Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulya'k K, van Der Meer J, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001;135:322-327
33. Sazci A, Ergul E, Kaya G, Kara I. Genotype and allele frequencies of the polymorphic methylenetetrahydrofolate reductase gene in Turkey. Cell Biochem Funct 2005; 23:51-54
34. Naess IA, Christiansen SC, Romundstad PR, Cannegieter SC, Blom HC, Rosendaal FR, et al. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population results from the HUNT 2 study. Br J Haematol 2008; 141:529-535
35. Gaustadnes M, Rudiger N, Rasmussen K, Ingerslev J. Intermediate and severe hyperhomocysteinemia with thrombosis. Thromb Haemost 2000; 83:554-558
36. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: Results from the MEGA study. Arch Intern Med 2007; 167:497-501
37. Kraaijenhagen RA, in't Anker PS, Koopman MMW, Reitsma PH, Prins MH, ven den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83:5-9
38. Erkekol FO, Ulu A, Numanoglu N, Akar N. High plasma levels of factor VIII: An important risk for isolated pulmonary embolism. Respirology 2006; 11:70-74
39. Oguzulgen IK, Ekim NN, Akar N, Demirel K, Kitapci M. The role of thrombophilic risk factors in the severity of pulmonary thromboembolism. Eur Respir J 2002; 19:709-711
40. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001; 3:139-148
41. Nicolaides AN. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 2005; 24:1-26
42. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002; 126:1281-1295
43. Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: An analysis using multiple-cause mortality data. Arch Intern Med 2003; 163:1711-1717
44. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240-1245
45. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336:393-398